Skip to main content
. Author manuscript; available in PMC: 2012 May 15.
Published in final edited form as: AIDS. 2011 May 15;25(8):1057–1064. doi: 10.1097/QAD.0b013e328346bd3e

Table 2.

Study retention and product adherence by treatment group

VivaGel VivaGel Placebo HEC Gel All Arms
Participants enrolled 22 21 18 61
Study retention for all visits 22 (100%) 21 (100%) 18 (100%) 61 (100%)
Percentage of gel use*
Excluding time on product hold
 0.0% 0 0 0 0
 0.1% – 49.9% 0 0 0 0
 50% – 79.9% 1 (5%) 0 1 (6%) 2 (3%)
 ≥ 80.0% 21 (95%) 21 (100%) 17 (94%) 59 (97%)
Including time on product hold
 0.0% 0 0 0 0
 0.1% – 49.9% 1 (5%) 0 0 1 (2%)
 50% – 79.9% 4 (18%) 1 (5%) 1 (6%) 6 (10%)
 ≥ 80.0% 17 (77%) 20 (95%) 17 (94%) 54 (89%)
*

Up to Week 2 visit